UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Journal of oncology pharmacy practice, 2019-04, Vol.25 (3), p.551-557

2019

Link zum Volltext

Verfügbarkeit prüfen

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy

Frontiers in oncology, 2023-01, Vol.12, p.1025455

2023

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting

JACC CardioOncology, 2020-09, Vol.2 (3), p.491-502

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Journal of clinical oncology, 2020-02, Vol.38 (6), p.576-583

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

European journal of cancer (1990), 2021-11, Vol.157, p.140-152

2021

Link zum Volltext

Verfügbarkeit prüfen

Epigenetics: A primer for clinicians

Blood reviews, 2016-07, Vol.30 (4), p.285-295

2016

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

The New England journal of medicine, 2023-09, Vol.389 (10), p.911-921

2023

Link zum Volltext

Verfügbarkeit prüfen

Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

Acta oncologica, 2017-10, Vol.56 (10), p.1327-1330

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1667: A pilot study correlating baseline plasma levels of adenosine 2A receptor (A2aR) with acute phase reactants in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1667-1667

2021

Link zum Volltext

Verfügbarkeit prüfen

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome: 1723

The American journal of gastroenterology, 2017-10, Vol.112, p.S934-S935

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P049-P049

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT115-CT115

2022

Link zum Volltext

Verfügbarkeit prüfen

Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

Acta oncologica (Stockholm, Sweden), 2017, Vol.56 (10), p.1327-1330

2017

Link zum Volltext

Verfügbarkeit prüfen

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Hepatology (Baltimore, Md.), 2022-10, Vol.76 (4), p.1000-1012

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1177-1187

2020

Link zum Volltext

Verfügbarkeit prüfen

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

JAMA oncology, 2020-12, Vol.6 (12), p.1952

2020

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Acta oncologica, 2018-05, Vol.57 (5), p.705-708

2018

Link zum Volltext

Verfügbarkeit prüfen

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European journal of cancer (1990), 2022-11, Vol.175, p.204-213

2022

Link zum Volltext

Verfügbarkeit prüfen

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3157-TPS3157

2022

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review

Frontiers in oncology, 2022-12, Vol.12, p.1023545

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1691: Clinical characteristics influencing survival in stage-IV non-small cell lung cancer treated with nivolumab: A single-institutional experience

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1691-1691

2018

Link zum Volltext

Verfügbarkeit prüfen

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.169-169, Article 169

2019

Link zum Volltext

Verfügbarkeit prüfen

Neuroendocrine carcinoma of luminal gastrointestinal tract

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16186-e16186

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(49)
Berichte
(5)

Sprache

Englisch
(54)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Oncology
(21)
Humans
(15)
Immunotherapy
(15)
Immune Checkpoint Inhibitors
(12)
Patients
(10)
Tumors
(8)
Aged
(7)
Female
(7)
Hepatocellular Carcinoma
(7)
Liver Cancer
(7)
Lung Cancer
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Immunology
(6)
Lung Neoplasms - Drug Therapy
(6)
Male
(6)
Metastasis
(6)
Monoclonal Antibodies
(6)
Retrospective Studies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

Epigenetics: A primer for clinicians

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

Abstract 1667: A pilot study correlating baseline plasma levels of adenosine 2A receptor (A2aR) with acute phase reactants in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome: 1723

Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer

Abstract 485: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study

Abstract CT115: Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+)

Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review

Abstract 1691: Clinical characteristics influencing survival in stage-IV non-small cell lung cancer treated with nivolumab: A single-institutional experience

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

Neuroendocrine carcinoma of luminal gastrointestinal tract

Suchergebnisse filtern